I'm LongbridgeAI, I can summarize articles.Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver for ROS1+ NSCLC in the U.S., Japan, and China. Through June 30, 2026, it generated ~760 new patient starts and $66 million in net revenue. The company holds $661 million in cash and securities, projecting profitability without additional funding. Safusidenib is enrolling in pivotal studies for astrocytoma, while its drug-drug conjugate platform remains preclinical.
- Nuvation Bio highlighted IBTROZI (taletrectinib) as a commercial driver, cleared for advanced ROS1+ NSCLC in the U.S., Japan, China. * U.S. launch metrics through June 30, 2026: about 760 new patient starts, USD 66 million net product revenue. * Cash, cash equivalents, marketable securities of USD 661 million as of June 30, 2026; path to profitability without additional funding. * Safusidenib positioned as a brain-penetrant IDH1 inhibitor; pivotal SIGMA study enrolling in high-risk astrocytoma, separate grade 2 phase 3 planned outside U.S. * Drug-Drug Conjugate platform remains preclinical; candidates under evaluation for solid tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here